Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer

Published:2019-03 Issue:3 Volume:39 Page:1463-1468
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

NAKASHIMA KAZUHISA,AKAMATSU HIROAKI,MURAKAMI HARUYASU,NIWA TAKASHI,IWAMOTO YASUO,OZAWA YUICHI,YOKOYAMA TOSHIHIDE,SHODA HIROYASU,YAMAMOTO NOBUYUKI,YOSHIOKA HIROSHIGE,MASUDA KEN,NAITO TATEAKI,MORI KEITA,TAKAHASHI TOSHIAKI

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426;Translational Cancer Research;2023-04

2. The emergence of nanoporous materials in lung cancer therapy;Science and Technology of Advanced Materials;2022-07-20

3. First‐line nab ‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study;Cancer Medicine;2021-10-20

4. International consensus on severe lung cancer—the first edition;Translational Lung Cancer Research;2021-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP